Todd Davis: Ligand Raises 2025 Guidance Amid Strong Royalty Portfolio Momentum
Todd Davis, Chief Executive Officer and Director at Ligand Pharmaceuticals, shared on LinkedIn:
“Today Ligand Pharmaceuticals announced second quarter results and raised financial guidance for 2025, reflecting the strong momentum across our royalty portfolio. I am very proud of our team’s execution and our ongoing commitment to disciplined capital deployment.
During the call this morning, I discussed several exciting developments and catalysts on both the commercial and development side of our portfolio. These include the global commercialization of Ohtuvayre under Merck and the potential expansion of Travere’s Filspari into FSGS. We are fortunate to be invested in a number of exciting therapies that have the potential to transform patients’ lives.
Ligand’s diverse portfolio of commercial royalty-generating programs and a robust late-stage pipeline position us well to achieve our strategic goals, ensuring sustained growth and long-term value for our shareholders.
You can read our earnings results here.”
More posts featuring Todd Davis.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023